Corvus Pharma's Q2 net loss widens
Overview
Corvus Q2 net loss widens to $8.0 mln from $4.3 mln a year ago
Company raised $35.7 mln from stock warrants, boosting cash reserves to $74.4 mln
Advancing soquelitinib in trials for atopic dermatitis and T cell lymphoma
Outlook
Company to report data from Phase 1 trial extension cohort 4 in Q4 2025
Phase 2 trial for soquelitinib in atopic dermatitis to start before year-end
Angel Pharmaceuticals to initiate Phase 1b/2 trial in China for soquelitinib
Enrollment continues in Phase 3 trial for PTCL and Phase 2 trial for ALPS
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| -$0.1 |
|
Q2 Net Income |
| -$8 mln |
|
Q2 Basic EPS |
| -$0.1 |
|
Q2 Operating Expenses |
| $10.26 mln |
|
Q2 Operating Income |
| -$10.26 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Corvus Pharmaceuticals Inc is $13.00, about 67.9% above its August 6 closing price of $4.17
Press Release: ID:nGNX5Ql7Yj
